CTLA4 and mucosal melanoma: A multicenter retrospective study conducted in France revealed that in 151 patients with mucosal melanoma, treatment with anti-CTLA-4 or anti-PD-1 antibodies provided an ORR of 11.9% (95% CI, 7.2–18.2) and a median OS of 15.97 months (interquartile range, 6.89–27.11 months) (130).